23^rd World Dermatology Congress June 20-21, 2022 Paris, France

Biography:

Dr. Clivia Oliveira is an Associate Professor in Clinical Dermatology, at the Federal University of Para, Brazil. She received a Bachelor’s Degree from the Medical School of State University of Para, in 1993, completed internal medicine residency and  fellowship in dermatology in 1996, and Master’s Degree in Tropical Medicine from the Federal University of Para, in 2000. She’s currently in the process of obtaining a Dermatology doctorate  degree from University of Sao Paulo, Brazil. Dr. Oliveira, is an active member of the Board of National Dermatology Society in Brazil where she is responsible for library coordination. Dr. Oliveira is also a prestigious author of a number of papers, some of her better-known titles include” Consensus on the therapeutic management of rosacea – Brazilian Society of Dermatology”.

Abstract:

Rosacea is a chronic inflammatory disease of the skin, relatively more frequent in women over 30 with a low phototype and proven genetic predisposition. Although its etiology is unknown and possibly multifactorial, the immunological abnormality, associated with neurovascular dysregulation and triggering factors, are important elements in its pathophysiology, which lead to the main changes of inflammation, vasodilation, and angiogenesis that are responsible for the clinical manifestations. Despite the lack of cure, numerous therapeutic options are available for the different clinical presentations of the disease, with satisfactory responses. Objective To reach a consensus, with recommendations from experts, on the therapeutic management of rosacea suitable to the Brazilian setting. Methods The study was conducted by five specialized dermatologists from university centers, representatives of the different Brazilian regions, with experience in rosacea, who were appointed by the Brazilian Society of Dermatology. Based on the adapted DELPHI methodology, the experts contributed through an updated bibliographic review of the scientific evidence, combined with personal experiences. Results The group of experts reached a consensus on the relevant aspects in the therapeutic management of rosacea, providing information on epidemiology, pathophysiology, triggering factors, clinical condition, classification, quality of life, and comorbidities. Consensus was defined as approval by at least 90% of the panel.

Biography:

I have completed my postgraduation at the age of 27 years from Yonsei university Wonju college of medicine, South Korea. I have published 5 papers in reputed journals. Now I am doing Residency in Dermatology from Kangbuk Samsung Hospital, South Korea.

Abstract:

Endocrine mucin-producing sweat gland carcinoma (EMPSGC) is a rare, low-grade adnexal carcinoma that most commonly presenting on the periorbital skin of elderly women. It was first reported by Flieder et al in 1997 and is recently proposed as an in situ precursor of mucinous carcinoma with neuroendocrine features. EMPSGC and associated mucinous carcinoma likely to behave more indolently than non-endocrine subtype.

A 62-year-old male presented with a year history of an asymptomatic, skin-colored nodule on the left cheek near the edge of lower eyelid. Based on the clinical impression of intradermal nevus, a punch excisional biopsy was performed. Histopathologic findings demonstrated well-circumscribed, dermal nodule comprising bland, uniform tumor cells with stippled chromatin. Also, floating tumor nests were demonstrated within abundant mucin pool. Staining for p63 revealed stromal myoepithelial cells. Immunohistochemistry stains were positive for CK7, CD56, synaptophysin, and chromogranin A, rendering a diagnosis of EMPSGC-associated neuroendocrine primary cutaneous mucinous carcinoma (PCMC). Owing to unclear resection margin, the patient is scheduled to undergo wide excision.

Although rare, dermatologists must be aware of EMPSGC-associated neuroendocrine PCMC as these tumors can be locally destructive and cosmetically disfiguring. To our knowledge, this is the first report in the Korean literature.

Biography:

I have completed my postgraduation at the age of 26 years from Kosin university college of medicine, South Korea. I have published 1 papers in reputed journals. Now I am doing Residency in Dermatology from Kangbuk Samsung Hospital, South Korea.

Abstract:

Angiomyolipoma (AML) is a tumor composed of adipocytes, smooth muscle, and blood vessels, commonly associated with kidney as a solitary mass. Extrarenal AMLs have been reported in liver, nasal cavity, oral cavity, heart, colon, lung, and skin. Cutaneous AML is a rare benign tumor and located in the acral skin or on the ear. While 30% of renal AMLs are associated with tuberous sclerosis (TS), none of cutaneous AML cases were reported to be related to TS to date.

A 79-year-old male presented with a grayish dermal mass on the right great toe for a decade. Ultrasonography revealed a well-defined, oval, hyperechoic lesion with no significant increased vascularity in the subcutaneous tissue. The 0.8 × 0.4 × 0.4 cm sized circumscribed nodule was excised totally. Histopathologic examination revealed a proliferation of smooth muscle bundles, blood vessels, and mature adipose tissue. The muscle component was predominant without any atypia or mitoses. In immunohistochemistry analysis, SMA was positive in smooth muscle cells, while S100 and CD31 were negative. Finally, the patient was diagnosed as cutaneous AML.

To our knowledge, only 5 cases of cutaneous AML have been reported in the Korean literature. Herein, we report a rare case of cutaneous AML which developed on the right great toe.

Biography:

Prof. Giusto Trevisan is graduated in Medicine and Surgery from the University of Trieste. Since 1985 he has been Associate Professor of Dermosyphilopathic Clinic. Since 1975 he has been the Director of the Clinic of Dermatology and Venereology of the University of Trieste and since 1977 Director of the School of Specialization in Dermatology and Venereology until 31 October 2017.

Abstract:

Borreliaceae is a family of the phylum Spirochaetales and includes two genera, Borrelia and Cristispira genus.

Borrelia genus is divided into three groups, namely Lyme group (LG), Echidna‐Reptile group (REPG) and Relapsing Fever group (RFG).

All Borrelia species have an obligate parasitic lifestyle, as they depend on their hosts for most of their nutritional needs. Borreliæ are transmitted among vertebrate hosts by arthropod vectors (ticks and lice). Transtadial transmission within their carriers occurs for the Borreliæ RF Group, while this does not (or rarely occurs) for the Borreliæ Lyme Group.

Phylogenetic data demonstrated that these two groups are genetically similar but distinct, forming independent clades sharing a common ancestor [1].

In nature, the vectors of LB belong to the genus Ixodes spp. frequently found in the Northern Hemisphere, while the vectors of RF are usually the soft-ticks (Ornithodoros spp.). Borreliae share a unique genomic structure consisting of a single highly conserved linear chromosome and several linear and circular extrachromosomal plasmids which can vary widely between strains [2]. In addition to Lyme and RF borreliosis, an intermediate group, called Echidna-Reptile borreliosis, has recently been identified.

Lyme disease (LD) is caused by the spirochæte Borrelia burgdorferi sensu lato (s.l.) and transmitted to humans by the bite of a hard tick of the genus Ixodes, and LD reservoir are usually small rodents [3]. LD is present in America, Eurasia, Africa, while its presence in Australia is not yet well documented.

Not all Borreliæ Lyme Groups cause this disease in humans. Of the 23 Borreliæ burgdorferi s.l. currently known only 9 have been identified in human infection [4], namely Borrelia burgdorferi sensu stricto, B. afzelii, B. bavarensis, B. bissettii, B. garinii, B. lusitaniae, B. spielmani, B. valaisiana, and B. mayonii. LD is an organotropic infection, but there is also a spirochætemic form, caused by Borrelia mayonii, which gives fever similarly to the Borreliosis RF Group [5]. A third variant of LD is Baggio-Yoshinari Syndrome (BYS) [6], which is transmitted by another hard tick, Amblyomma cajennense. This Borrelia has not been isolated in culture, therefore its membership in the Lyme Group is not yet proven. All three of these Sub-Groups can manifest early with erythema migrans. Clinical features of LD are wide and variable, with clinical manifestations linked to distinct tissue tropisms of specific Borrelia burgdorferi s.l. genospecies [7]. The early infection is localized and, in the absence of treatment, the spirochete can spread [8]. The organs most frequently involved are skin, joints, muscles, nervous system, heart and eyes [9]. B. burgdorferi s.s. is more often associated with Lyme arthritis, Borrelia garinii with neuroborreliosis and B. afzelii with acrodermatitis chronica atrophicans.

Biography:

I have completed my postgraduation at the age of 26 years from Daegu Catholic university school of medicine, South Korea. I have published 1 papers in reputed journals. Now I am doing Residency in Dermatology from Kangbuk Samsung Hospital, South Korea.

Abstract:

Pyogenic granuloma (PG), the most common benign vascular tumor, does not involute spontaneously. Thus, several long-pulsed (LP) lasers can be an effective treatment option. While the treatment parameters used for common LP lasers are well-known, the objective therapeutic endpoints associated with LP laser therapy in PG has not yet been established. Thus, we tried to specify several dermoscopic features which help clinicians determining the therapeutic endpoint.

 A 56-year-old male presented with an easily bleeding, 6 × 3 mm sized, reddish pyogenic granuloma located on the volar side of the left 4th finger. The lesion was treated with a pulsed-dye laser (PDL) using the following parameters: 7-mm spot size, 2–6-millisecond pulse duration, and radiant exposure of 7–9 J/cm2 with level 1 air cooling. Immediately after PDL, several changes in the dermoscopic structures of PG were observed. Post-laser dermoscopic patterns were composed of newly-emerged dusky violaceous homogenous areas, increased whitish homogenous areas, and focal crusted rupture. Similar findings were detected with other patients who were treated identically for their PG lesions.

As the patient could reach the termination of the treatment, we report the described dermoscopic changes as the therapeutic endpoints of pyogenic granuloma treated with LP laser.

Biography:

Anthony M. Rossi M.D. is a board-certified dermatologist and Micrographic Surgeon at the Memorial Sloan Kettering Cancer Center and an assistant professor at Weill Cornell Medical College.  He trained in dermatologic surgery, cosmetic and laser dermatology, and advanced cutaneous oncology at the Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine. His interests include non-invasive imaging of cutaneous tumors; laser and light based treatments of skin cancers; as well as the quality of life impact of cosmetic procedures. He also has a keen interest in the utilization of reflectance confocal microscopy in the skin.

Abstract:

Cutaneous signs of aging and skin sensitivity, both growing fields in dermatology, are provoking tremendous interest with increasing populations declaring to have skin sensitivity. Specific individuals show heightened sensitivity to vast arrays of noxious stimuli including physical irritants and environmental factors which not only lead to perceived feelings of sensitivity but also cutaneous signs, such as erythema.  The human thermoreceptor TRPV1 is known to play a key role in sensitive skin and skin aging, therefore, its inhibition with targeted therapy should help reduce skin reactivity. 

A five amino acid sea anemone peptide with TRPV1 inhibition properties along with niacinamide and hyaluronic acid were incorporated into novel topical skincare formulations for addressing signs of skin aging and sensitivity.

Multiple clinical trials testing the RossiDerm MD ™ line of products were carried out. Healthy M/F(30- 63y), of all races with self-perceived sensitive facial skin, mild/moderate lines/wrinkles, uneven skin tone, noticeable pores, and skin roughness who provided written informed consent and met the inclusion/exclusion criteria were enrolled. A trained grader evaluated various skin attributes at baseline, immediately after test product application and at Week4. Chromameter™ was used to measure skin redness, hyperpigmentation, brightness/radiance  and  the Cutometer® to measure skin elasticity. Digital images (VISIA^®-CR) of lines/wrinkles, visible spots, red feature, texture and pores were taken and analyzed using Vaestro^®analyses. Consumer perception was collected via Self-Perception Questionnaires (SPQ).

With use of topical skin care formulations targeting the TRPV1 skin receptor, results from our multiple clinical trials confirmed by clinical grading, instrument measurements, Vaestro^® image analysis and subject’s self-perception showed improvement in cutaneous signs of aging and skin sensitivity.

In conclusion, TRPV-1 targeted therapy helps reduce cutaneous aging and skin sensitivity in overreacting to environmental stimuli and this can be further exploited in management of highly prevalent skin conditions like atopic dermatitis, acne and others.

Biography:

Ahmad KHODR, Ph.D. After my “Maîtrise” in Biochemistry in Lebanon, I have been selected by the International Scholarship program of the Ecole Normale Supérieure de Cachan to do my master’s in Microbiology and Biochemistry. Following the masters, I have conducted a Ph.D. research program in Microbiology and Molecular Biology at the ENS Cachan, France focusing on the regulation of virulence of Enteropathogenic E. coli by H-NS family proteins. I have carried-out a Post-Doc research program at the Pasteur Institute Paris, where I have applied Transcriptomics and Next Generation Sequencing tools to decipher virulence mechanisms of Legionella pneumophila. Currently, I Lead the Microbiology innovation Lab. and transversal projects dedicated to Microbiome Analysis and Visualization at L’Oréal Research and Innovation working on translating innovative Microbiome derived concepts to cosmetic products. I published and presented my research work in well recognized international peer reviewed journals and congresses.

Abstract:

The microbiome, as a community of microorganisms and their structural elements, genomes, metabolites/signal molecules, has been shown to play an important role in human health, with significant beneficial applications for gut health. Skin microbiome has emerged as a new field with high potential to develop disruptive solutions to manage skin health and disease. Despite an incomplete toolbox for skin microbiome analyses, much progress has been made towards functional dissection of microbiomes and host-microbiome interactions. A standardized and robust investigation of the skin microbiome is necessary to provide accurate microbial information and set the base for a successful translation of innovations in the dermo-cosmetic field. The most promising skin and gut-derived microbiome interventional strategies are presented, along with regulatory, safety, industrial, and technical challenges related to a successful translation of these microbiome-based concepts/technologies in the dermo-cosmetic industry.

Biography:

Board-certified Plastic, Reconstructive and Microsurgeon, working as Associate Professor in Sher-i-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, India. Areas of interest are reconstructive and microsurgery, hand surgery, cleft and faciomaxillary, burn management and rehabilitation and wound care and research. Has 36 publications in various peer reviewed journals. Editorial Board Member of our institutional journal. In-charge of academics and research of post-doctoral and National Board fellows of our department. Life-time member of Association of Plastic Surgeons of India, National Academy of Burns-India, Indian Society for Surgery of Hand, British Burn Association, Asia Pacific Burn Association, European Burn Association, Diabetic Foot Society of India. Editorial Board member and a reviewer of several national and international journals of repute. Work as a team member. Always keen on teaching and learning.

Abstract:

Merkel cell carcinoma (MCC) is an infrequent, rapidly growing skin neoplasm that carries a greater probability of regional lymph node involvement, and a grim prognosis in advanced cases. While it is seen predominantly in old age in sun-exposed body parts, the prevalence varies among different races and geographical regions. Merkel cell polyomavirus and UV radiation-induced mutations contribute to its etiopathogenesis. The clinical presentation of MCC lacks pathognomonic features and is rarely considered highly at the time of presentation. Histopathological examination frequently reveals hyperchromatic nuclei with high mitotic activity, but immunohistochemistry is required to confirm the diagnosis. Sentinel lymph node biopsy (SLNB) and imaging are advised for effective staging of the disease. Multimodal management including surgery, radiation therapy, and/or immunotherapy are deployed. Traditional cytotoxic chemotherapies may result in an initial response, but do not result in a significant survival benefit. Checkpoint inhibitors have dramatically improved the prognosis of patients with metastatic MCC, and are recommended first-line in advanced cases. There is a need for well-tolerated agents with good safety profiles in patients who have failed immunotherapies.

Biography:

Maria-Eleni Paroikaki is currently a Year 4 medical student at Imperial College London. She has a special interest in dermatology and is hoping to pursue a career in the field in the future. She completed her primary and secondary education at the Hellenic American Educational Foundation in Athens, Greece, from which she graduated in 2018. She is a member of the British Association of Dermatology, the Royal Society of Medicine and the British Medical Association, as well as secretary of the Dermatology Society of Imperial College London. During the summer, she had the pleasure to work and be co-author of a worldwide review on the “Cutaneous Complications of mRNA and AZD1222 COVID-19 Vaccines”, which got published in the “Microorganisms” journal. Currently, she is working on a research project around leprosy, as part of her intercalated BSc degree in Medical Humanities, Philosophy and Law.

Abstract:

Biography:

RGJ-19 recipient, Program in Biotechnology, Kasetsart University (B.Sc., 2011), Program in Biotechnology, Chulalongkorn University (M.Sc., 2014), Ph.D. program in Biomedicinal Chemistry, Department of Biochemistry and Microbiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University (2021), TRF-DAAD Research-based Mobility Scheme (2019/2020). Focus of interest (Cancer cells, melanoma, melanogenesis, melanocyte stem cells). 

Abstract:

Hypopigmentation is a condition of low melanin production occurring in eye, skin and hair.  Until now, there has been no recommended remedies with high efficacy and human safety profile for hypopigmentation treatment. The flavonoid containing extracts from Dalbergia parviflora was shown to stimulate melanin production in B16F10 mouse melanoma cells. However, the regulatory mechanisms of the extracts on melanogenesis has not been thoroughly investigated. Here in, the inducing effect of D. parviflora extracts on the expression level of tyrosinase in mouse B16F10 & human MNT1melanoma cells was firstly revealed. The cells were treated with 0-50 µg/ml of D. parviflora extracts for 24-72 h for evaluation of cytotoxicity, mode of cell death and proliferative effect. Melanin production and tyrosinase activity were observed at non-toxic concentration of D. parviflora extracts. Determination of mRNA and expression level of melanin regulating proteins were performed by real-time RT-PCR and western blotting, respectively. Tyrosinase activity and melanin content were significantly increased in both B16F10 & MNT1 cells treated with D. parviflora at 0.1-10 µg/ml for 72 h. Despite of the up-regulation of tyrosinase mRNA at 48 h in mouse B16F10 cells, there was no alteration on mRNA of MITF, a transcription factor mediating tyrosinase expression in melanoma cells after incubation with 10 µg/ml of the extracts for 24-72 h. Interestingly, in mouse cells the translocation of MITF from cytoplasm into nuclease were presented in early at 24 h of D. parviflora extracts treatment. These results indicated that D. parviflora extracts stimulated the melanin production and up-regulated tyrosinase expression through modulation on MITF translocation in melanin generating cells. The information obtained from this study strengthen the potential development of D. parviflora extracts as an effective treatment with high human safety for hypopigmented disorders. 

Biography:

Dr. Frederick H. Silver is a Professor of Pathology and Laboratory Medicine and at Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey. He did his Ph.D. in Polymer Science and Engineering at M.I.T. with Dr. Ioannis Yannas, the inventor of the Integra artificial skin, followed by a postdoctoral fellowship in Developmental Medicine at Mass General Hospital in Boston, MA with Dr. Robert L. Trelstad, a connective tissue pathologist. A US Patent has been granted and a European Patent has been filed on vibrational evaluation of tissues. His interests include the structure and properties of extracellular matrix (ECM) in health and diseases and mechanobiology. The goal of his research is to apply techniques of polymer science to elucidation of physical biomarkers of disease. He has published numerous papers on skin biomechanics during the last 40 years.

Abstract:

Statement of Problem: Visual and dermoscopic observations are the standard of care for evaluating skin lesions that may be cancerous. By the year 2050 it is predicted that 50 million skin biopsies will be conducted in the USA each year which may overwhelm the current the screening abilities of the existing dermatological services. The need for new non-invasive technologies that can be used in conjunction with visual and dermoscopic analysis will be needed to meet the expanded demand for dermatological screening. The purpose of this study is to describe the results of skin cancer studies using vibrational optical coherence tomography to non-invasively quantitatively analyze the 3D cellular, blood vessel and collagen distribution in normal skin and cancerous lesions. VOCT applies audible sound and infrared light transversely from 3 cm above skin to measure the frequency dependence of the displacement of skin. The frequencies at which the maximum displacement occurs are the resonant frequencies of the skin major components. The resonant frequencies are converted into tissue stiffness by dividing by the tissue thickness based on the OCT images. Findings: Cancerous lesions contain new cellular resonant frequency peaks at 80Hz, 130Hz, and 260Hz that are not all present in normal skin or benign skin lesions. These peaks are associated with the increased stiffness of cells (80Hz), new blood vessels (130Hz) and fibrous tissue (260 Hz) that have been reported to stiffen cancerous lesions compared to normal skin. Using the OCT volume scan app and data from the raw images, 3D representation of the resonant frequency and location of cellular, fibrotic and blood vessel components of skin lesions can be analyzed non-invasively. Conclusion & Significance: VOCT in conjunction with visual inspection and dermoscopy can be used to quantitatively analyze difficult skin lesions such as melanomas.

Biography:

Dr. Alimuddin is the Associate Professor at Sultan Ageng Tirtayasa University, Indonesia.

Abstract:

Premature babies and low birth weight babies are not able to adapt to the environment. The incubator has a role to provide the right environmental conditions for premature babies and low birth weight babies. The condition of the baby such as weight and age are parameters that are always changing, which is what determines the temperature conditions in the right incubator. The development of technology for controlling and monitoring environmental conditions including temperature, humidity, oxygen, is important. When the baby is born, if there are abnormalities or abnormalities, including low baby weight, yellow eye color, and most critically, being born prematurely, it is not yet time to give birth. Many control and monitoring systems are used so far there are conventional and modern ones. The control and monitoring system has so far been isolated and not yet integrated and still uses one control system algorithm ON OFF, PID and Fuzzy Logic. There are several research results by the author using the PID Gain Scheduling control system for temperature and humidity in the baby incubator (1) resulting in a model of temperature and humidity in the incubator that can represent the physical characteristics of the temperature and humidity of the incubator has been designed properly, as evidenced by the data validation with an error value 5%. one temperature model and four humidity models have an error value of 2.202% from 438 samples and 2.944% 1.57%, 1.56%, 1.242% from 1038 samples. Adaptive control using Integral-Adaptive Gain Scheduling on temperature and PID-Adaptive Gain Scheduling for humidity in baby incubators can be well designed as evidenced by simulations using simulink on MATLAB software that the system output is able to reach and follow the constantly changing set point and scheduler variables. and the PID and Fuzzy Logic hybrid control system on temperature and humidity in an infant incubator [2] resulted in the temperature control system of the proposed controller being checked at the set point values ​​of 34 °C and 35 °C from the initial room temperature and humidity of 60% and 70%. The results showed that the proposed Fuzzy-PID temperature control has a faster response to reach the set point than using PID alone. However, the proposed controller faces little difficulty in reaching the set point when interference occurs from the output of the moisture mist actuator and due to fluctuations in the outside temperature of the incubator.

Biography:

Dr Nalini Kaul completed her PhD. from PGIME&R Chandigarh, India. Post- doctoral training from St Boniface General Hospital Winnipeg Canada and from the University of Southern California, USA. Soon after she took a Senior Scientist position at the University of Dallas, Texas. Following her return to Canada she worked as Technical Director on Clinical trials with a reputed CRO, moved on to hold a joint appointment as Sr. Director of Regulatory Affairs and Director of Clinical trials with another firm of repute. At present she is Vice President of Technical Services at a well reputed CRO serving North American and the UK. She has published 40 papers in national and international journals, has several book chapters to her credit and  has widely presented at conferences both nationally and internationally.

Abstract:

Our skin undergoes intrinsic aging (chronological aging) as well as extrinsic aging. Most lines and wrinkles are due to extrinsic aging caused by environmental factors and lifestyle choices like sun exposure, pollution, poor diet, smoking, alcohol use and not enough sleep. Multiple factors are responsible for the clinical signs of aging, chief being loss of hydration, dermal proteins and oxidative stress.

Cutaneous photoaging is characterized by fine lines, wrinkles, dryness, roughness, dullness, laxity, hyperpigmentation, pore size, loss of elasticity and firmness.  Skin needs additional supportive care including photoprotection with sunscreen and antioxidants. 

With increasing interest in non-surgical ways for improving facial signs of aging, there is no dearth of cosmetic antiaging products available presently and new introductions often. However, products vary widely in their efficacy and potency. Therefore, a well-rounded approach is needed, keeping the ingredients in mind, for execution in clinical testing. Appropriate assessment methods to detect improvement or not and its extent in reducing or delaying symptoms of facial skin aging severity should be employed. Skin aging is studied directly by clinical grading, various bio instruments, and indirect methods (including D-Squames®, silicone impressions and analyses). In addition, consumer perception, crucial to product success, provides valuable clues.

Our objective was to test efficacy and safety of anti-aging cosmetics on various antiaging attributes in clinical designs with 35 healthy volunteers (F-35-65 y). Assessments included visual and tactile evaluations for lines, wrinkles, roughness, skin tone, pores and hyperpigmentation by a trained grader, hydration with Corneometer®, brightness with Colorimeter®, elasticity, firmness with Cutometer®, Moisture mapping with MoistureMeter, digital photos with VISIA® CR, Vaestro® for image analyses, and volunteer self-perception. Our results showed product efficacy and safety and their extent, when studying various antiaging parameters.

In conclusion, use of a panoply of assessments including clinical grading, various non-invasive bioengineering techniques and self-perception yields a more complete assessment of a product’s antiaging skin effects. Besides proving efficacy and safety it also helps with claim substantiation. This information helps the consumer in making an informed decision in choosing a product that proactively reduces/delays signs of aging and makes them look and feel aesthetically upbeat at the same time.

Biography:

Dr. Anju Goyal is currently working as Professor & Head in Department of Pharmaceutical Chemistry at Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, India. She received her B.Pharmacy degree from Maharishi Dayanand University, Rohtak in 2002. She has completed her M.Pharmacy and Ph.D. Degree in Pharmaceutical Chemistry from Guru Jambheshwar University of Sciences & Technology, Hisar, Haryana, in 2004 and 2012 respectively.

Abstract:

Plant-based medicines have received a lot of attention in recent years because they've been employed to treat medical conditions since ancient times. The dose accuracy, dose effectiveness, and therapy, have all been based only on the observed symptoms. Current research has primarily focused on medicinal active phytoconstituents rather than crude drugs. Researchers have made tremendous advancement towards the development of “novel drug delivery systems” (NDDS) in order to increase therapeutic efficacy and decrease unwanted effects of bioactive molecules over the centuries. Bioactive molecules and plant extracts have been used to create a variety of novel drug formulations, including nano capsules, polymer micelles, liposomes, nanogel, nano capsules, phytosomes, nano-emulsions, transferosomes, microspheres, ethosomes, injectable hydrogels, polymeric nanoparticles, dendrimers, and more. Enhancement in solubility, therapeutic efficacy, bioavailability, stability, tissue distribution, protection from physical and chemical damage, and prolonged and targeted delivery are only a few among the enormous uses of the new formulations. The current review covers existing research and development of new formulations, particularly for herbal bioactive compounds, and highlights the findings.

Biography:

I have completed my postgraduation at the age of 25 years from Yonsei university college of medicine, South Korea. I have published 4 papers in reputed journals. Now I am doing Residency in Dermatology from Kangbuk Samsung Hospital, South Korea.

Abstract:

Elastosis perforans serpiginosa (EPS) is a rare disorder showing erythematous or skin-colored hyperkeratotic papules with a serpiginous or arcuate distribution. EPS classified as a primary perforating dermatosis and characterized by transepidermal elimination of abnormal elastic fibers with transepidermal perforating canals from dermis. Among various treatment modalities, standard treatment method has not been established.

We report a 33-year-old male patient with a 2-month history of grouped, multiple, annular-shaped, scaly erythematous papules (about 2 to 4 mm in size) on his right anterior neck. Dermoscopy of the plaques revealed central whitish structureless scar-like areas with a polymorphous vasculatures and irregularly arranged multiple keratotic yellowish papules. Histopathological analysis revealed increased brightly eosinophilic elastic fibers from the papillary dermis through the epidermis and clutch the dermis at the site of perforation of elastic fiber. Basophilic mass comprising degenerate epithelial cells, inflammatory debris was also seen. Immuno-histochemical analysis revealed degenerated dermal elastic fibers with elastic fiber stain and negative on Periodic acid-Schiff (PAS) and Masson’s trichrome stain. Based on these clinical, dermoscopic, and histological features, the lesion was diagnosed as EPS. After treatment with six session of the 585-nm pulsed-dye laser per 3 weeks, the lesion was cleared without any adverse events associated with laser treatment and no recurrence was observed for 2 months after therapy.

Biography:

Professor Liborija Lugović-Mihić, MD, PhD, has been working as a Dermatovenereologist at the Department of Dermatology and Venereology, Sestre Milosrdnice University Hospital Centre since 2002, where she is Head of Clinic and Head of the Laboratory. Since 2007 she has been a mentor for 15 doctoral theses, mostly focusing on inflammatory skin diseases. In 2015 she received the Ministry of Health Award for most efficient dermatologist (Croatia). She has published three books, numerous scientific and professional publications, as well as book chapters and has been cited by many authors. She has contributed to many national and international scientific projects as head researcher and associate researcher.

Abstract:

Chronic diseases such as atopic dermatitis (AD) can severely limit both specific and broad dimensions of daily functioning, significantly lowering a person’s quality of life due to itching, sleep disorders, consequent anxiety, and depression. Thus, AD is known to be a significant burden on patients, their families, and also on society. 

Materials and methods: This research study analyzed different aspects of AD patients' quality of life. We assessed AD severity by the SCORing Atopic Dermatitis (SCORAD) index, the Dermatology Life Quality Index (DLQI), the World Health Organization Quality of Life Brief Version (WHOQOL-BREF), the Brief Illness Perception Questionnaire (Brief IPQ), and the Crown-Crisp Experiential Index (CCEI), which analyzes personality traits. The study included 84 AD patients in different stages of the disease (42 with clinical manifestations and 42 in remission). 

Results: SCORAD values correlated positively and linearly with DLQI (p<0.001) and with AD impact on life, disease control, and disease symptoms (p≤0.023). DLQI was also related to certain personality characteristics (free-floating anxiety disorder, obsession, somatization, and depression; p≤0.032). Symptomatic AD patients had a significantly more impaired DLQI than asymptomatic patients (p<0.001), and the two groups differed in some IPQ dimensions but not in the WHOQOL-BREF dimensions and personality traits (CCEI). 

Conclusion: The chronic, recurrent, and debilitating nature of AD significantly reduces patient quality of life. AD patient quality of life is dependent not only on disease severity but is also influenced by patient personality characteristics (anxiety disorder, obsession, somatization, depression). Thus, it is necessary to take these factors into account when analyzing AD patients’ quality of life predictors. These findings suggest that improving AD patients’ quality of life requires clinicians to consider a multidisciplinary treatment approach with psychological support strategies to create effective, patient-specific therapy regimens. 

Biography:

Gary Pekoe, PhD, is currently Chief Scientific Officer of Alphyn Biologics, Inc. Dr. Pekoe earned a PhD in Pharmacological Toxicology from West Virginia University, Morgantown, West Virginia, USA. Among his many accomplishments, Dr. Pekoe led the successful Bactroban® New Drug Application which was the first ever single agent prescription topical product approved by FDA and generated over $1 billion in sales for GSK. Dr. Pekoe has authored numerous scientific publications.

Neal Koller, is currently Chief Executive Officer of Alphyn Biologics, Inc. Mr. Koller earned a Bachelor of Science degree in Biology with secondary emphasis in Chemistry from University of Richmond, Richmond, Virginia, USA. Among his many accomplishments, Mr. Koller has been responsible for multiple therapeutic device and drug development, clinical trial, regulatory approval and or commercialization programs including the technology leading French 5® cardiac catheter line, Angio Seal® Vascular Closure System, Cardioscan® Cardiac Auscultation System and PluroGel® burn and wound products.

Abstract:

Atopic dermatitis (AD) is an inflammatory skin disease. 1 Staphylococcus aureus bacteria and its highly infectious and difficult to kill MRSA drug resistant variant (S. aureus and MRSA) have been shown to make AD worse and to prevent its healing. 2 AD generally presents early in life and maintains a lifetime prevalence in approximately 20% of populations. 1 The present study demonstrated the capability of a novel drug substance with multiple bioactive compounds (NDS) to target the multiple problems of AD, specifically the inflammation and associated pruritus (itch) of AD, and, the S. aureus and MRSA that exacerbate AD and prevent its healing. The present study utilized the Folin-Ciocalteu test (FC) to evaluate the NDS antioxidant activity. The FC test is a direct indicator of antiinflammatory activity. This study further evaluated the anti-bacterial activity of the NDS utilizing the Minimum Inhibitory Concentration (MIC) test, the Zone of Inhibition (ZoI) test and the Time Kill test. The results of the FC test demonstrated the NDS has very high antioxidant activity tying the NDS to anti-inflammatory and anti-pruritic capability for AD. The results of the MIC test, ZoI test and the Time Kill test showed the NDS is highly effective in killing S. aureus and MRSA, as well as other Gram positive and Gram negative multi drug resistant bacteria including Streptococcus pyogenes and Pseudomonas aeruginosa, demonstrating the NDS potential effectiveness in eliminating the bacterial causes of AD. In summary, the present study demonstrated the NDS to be a promising potent therapeutic for AD. These results additionally suggest the NDS may also work singularly as an effective anti-inflammatory or as an effective broad-spectrum antibiotic. The NDS is currently in a Phase 2a human clinical trial to uniquely treat both infected and non-infected AD.

Biography:

I have completed my postgraduation at the age of 25 years from Wonkwang university school of medicine, South Korea. I have published 2 papers in reputed journals. Now I am doing Residency in Dermatology from Kangbuk Samsung Hospital, South Korea.

Abstract:

With a widespread administration of COVID-19 vaccines, cutaneous reactions have been reported. Here, we report several cases of pityriasis rosea-like eruptions (PR-LE) developing after COVID-19 vaccination.

Three patients presented with generalized, erythematous, scaly plaques on the trunk following mRNA COVID-19 vaccination. Multiple, discrete, about 1.0 cm sized, oval to round, salmon-colored plaques were distributed along the lines of cleavage. Patients had a similar history of a primary solitary plaque on waist, neck and abdomen each preceding a secondary eruption of smaller lesions. Clinically, diagnosis of PR-LE was made. Supporting this, laboratory tests were non-specific and skin biopsies showed foci of parakeratosis overlying spongiotic epidermis, erythrocytes extravasated in the superficial dermis, and superficial lymphocytic infiltration. Virological investigation for HHV-6/7 reactivation was not performed. Two reported reactions after the first dose, and one after the booster dose. The symptom onset took from a day up to a month. Only one had pruritus. In common, the eruption resolved at follow-up visit.

As only a few cases of PR-LE have been reported to develop after vaccinations, the causal relationship between PR-LE and COVID-19 vaccination seems noteworthy. Herein, we report pityriasis rosea-like eruptions as a possible adverse effect of COVID-19 vaccination.

Biography:

Education - 2016 – 2019: University of Liverpool, United Kingdom MBChB. Undergraduate entry programme. 2013 – 2016: International Medical University, Malaysia (IMU) MBBS. Pre-clinical. Partner medical school program to University of Liverpool. Qualifications – 2019: University of Liverpool Medical School (MBChB Studies). 2021: Full MRCP (UK) Diploma (London).

Abstract:

Introduction:

Atopic dermatitis (AD) is a common inflammatory skin disease distinguished by intense pruritus, and excoriations. Most can be treated with topical agents. Some requires systemic therapy; however they have multiple adverse effects and limited efficacy. Dupilumab is the first targeted biologic agent, recently approved for the treatment of moderate-to-severe AD. It is a fully-human monoclonal antibody and blocks the shared IL-4 receptor which is proposed to be a critical pathway in allergic diseases.

Methods:

A search through Pubmed, Medline, DermNet, BAD Journals, Uptodate, and Embase was performed on use of dupilumab in treating moderate-to-severe AD. The articles found were reviewed and analysed.

Results:

The efficacies of different dupilumab doses were analysed and it showed that patients treated with dupilumab 300 mg weekly had similar clinical outcomes to those receiving 300 mg every alternate week. Therefore, NICE Guidance has recommended a dose of dupilumab every alternate week so as to be cost-effective in the NHS. Its safety profile is considered superior to that of immunosuppressive drugs, as it specifically blocks signals from IL-4 and IL-13 only. Common side effects of dupilumab are conjunctivitis, headaches and cold sores.

Conclusion:

The recommended criteria on indications to initiate Dupilumab treatment for moderateto-severe AD in adults is when the disease has not responded adequately to at least one other systemic therapy, or these are contraindicated or not tolerated. An adequate response is seen if there is at least 50% reduction in the EASI 50 at least a 4-point reduction in the DLQI from initiation of treatment.

Biography:

Abstract: